Patents by Inventor Tikva Vogel
Tikva Vogel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7087722Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.Type: GrantFiled: January 27, 2000Date of Patent: August 8, 2006Assignee: Savient Pharmaceuticals, Inc.Inventors: Tikva Vogel, Avigdor Levanon, Moshe Werber, Rachel Guy, Amos Panet
-
Publication number: 20050152906Abstract: The present invention provides antibodies that bind an epitope of PSGL-1 comprising the motif D-X-Y-D, wherein X represents any amino acid or the covalent linkage between D and Y, and Y is sulfated, which antibody can be complexed with one or more copies of an agent. The antibodies of the invention can be used in a method of inducing antibody-dependent cell cytotoxicity and/or stimulating natural killer (NK) cells or T cells. In addition, by administering these antibodies to a patient in need thereof, a method of inducing cell death is provided. A method of preventing infection by a virus (e.g., HIV) by administering to a patient in need thereof an antibody of the present invention is also provided. The, present invention also provides a method of introducing an agent into a cell that expresses sulfated PSGL-1 by coupling or complexing an agent to an antibody of the present invention and administering the complex to the cell.Type: ApplicationFiled: June 30, 2004Publication date: July 14, 2005Inventors: Avigdor Levanon, Tikva Vogel, Daniel Plaksin, Tuvia Peretz, Boaz Amit, Lena Cooperman, Yocheved Hagay, Esther Szanton, Yariv Kanfi, Rachel Ben-Levy, Tali Szrajber
-
Publication number: 20040002450Abstract: The present invention provides epitopes present on cancer cells and important in physiological phenomena such as cell rolling, metastasis, and inflammation. Therapeutic and diagnostic methods and compositions using antibodies capable of binding to the epitopes are provided.Type: ApplicationFiled: December 31, 2001Publication date: January 1, 2004Inventors: Janette Lazarovits, Yocheved Hagay, Daniel Plaksin, Tikva Vogel, Abraham Nimrod, Hagit Mar-Ham, Ester Szanthon, Tamar Richter, Boaz Amit, Lena Cooperman, Tuvia Peretz, Avigdor Levanon
-
Publication number: 20040001839Abstract: The present invention provides epitopes present on cancer cells and important in physiological phenomena such as cell rolling, metastasis, and inflammation. Therapeutic and diagnostic methods and compositions using antibodies capable of binding to the epitopes are provided.Type: ApplicationFiled: December 31, 2001Publication date: January 1, 2004Inventors: Avigdor Levanon, Yocheved Hagay, Daniel Plaksin, Tikva Vogel, Abraham Nimrod, Hagit Mar-Haim, Ester Szanthon, Tamar Richter, Boaz Amit, Lena Cooperman, Tuvia Peretz, Janette Lazarovits
-
Publication number: 20040001822Abstract: The present invention provides epitopes present on cancer cells and important in physiological phenomena such as cell rolling, metastasis, and inflammation. Therapeutic and diagnostic methods and compositions using antibodies capable of binding to the epitopes are provided. Methods and compositions according to the present invention can be used in diagnosis of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, and inflammatory disease.Type: ApplicationFiled: December 31, 2001Publication date: January 1, 2004Inventors: Avigdor Levanon, Yocheved Hagay, Daniel Plaksin, Tikva Vogel, Abraham Nimrod, Hagit Mar-Haim, Esther Szanthon, Tamar Richter, Boaz Amit, Lena Cooperman, Tuvia Peretz, Janette Lazarovits
-
Patent number: 6121426Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.Type: GrantFiled: August 11, 1997Date of Patent: September 19, 2000Assignee: Bio-Technology General Corp.Inventors: Tikva Vogel, Avigdor Levanon, Moshe Werber, Rachel Guy, Amos Panet
-
Patent number: 6054291Abstract: An improved vector upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.Type: GrantFiled: June 9, 1997Date of Patent: April 25, 2000Assignee: Bio-Technology General Corp.Inventors: Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel
-
Patent number: 5965383Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus-or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.Type: GrantFiled: March 24, 1995Date of Patent: October 12, 1999Assignee: Bio-Technology General Corp.Inventors: Tikva Vogel, Avigdor Levanon, Moshe Werber, Rachel Guy, Amos Panet
-
Patent number: 5869616Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.Type: GrantFiled: April 8, 1997Date of Patent: February 9, 1999Assignee: Bio-Technology General Corp.Inventors: Tikva Vogel, Avigdor Levanon, Moshe M. Werber, Rachel Guy, Amos Panet, Jacob Hartman, Hadassa Shaked
-
Patent number: 5759816Abstract: An improved vector upon introduction into a suitable host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site; an ATG initiation codon or DNA which is converted into an ATG initiation codon upon insertion of the desired gene into the vector; a second restriction enzyme site for inserting the gene in phase with the ATG codon; a T.sub.1 T.sub.2 rRNA transcription termination sequence; an origin of replication and a gene associated with a selectable or identifiable phenotypic trait manifested when the vector is present in the host. The distance between the 3' end of the P.sub.L O.sub.Type: GrantFiled: May 25, 1995Date of Patent: June 2, 1998Assignee: Bio-Technology General Corp.Inventors: Amos B. Oppenheim, Avigdor Levanon, Hilla Locker-Giladi, Marian Gorecki, Tikva Vogel
-
Patent number: 5679320Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imagifig a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.Type: GrantFiled: June 14, 1994Date of Patent: October 21, 1997Assignee: Bio-Technology General Corp.Inventors: Tikva Vogel, Avigdor Levanon, Moshe M. Werber, Rachel Guy, Amos Panet, Jacob Hartman, Hadassa Shaked
-
Patent number: 5637495Abstract: An improved vector upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.Type: GrantFiled: November 14, 1994Date of Patent: June 10, 1997Assignee: Bio-Technology General Corp.Inventors: Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel
-
Patent number: 5455158Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.Type: GrantFiled: May 4, 1993Date of Patent: October 3, 1995Assignee: Bio-Technology General Corp.Inventors: Tikva Vogel, Avigdor Levanon, Moshe M. Werber, Rachel Guy, Amos Panet
-
Patent number: 5270030Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.Type: GrantFiled: May 21, 1990Date of Patent: December 14, 1993Assignee: Bio-Technology General Corp.Inventors: Tikva Vogel, Avigdor Levanon, Moshe M. Werber, Rachel Guy, Amos Panet
-
Patent number: 5256546Abstract: A plasmid for the production of porcine growth hormone or an analog thereof which upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of DNA encoding porcine growth hormone and production of porcine growth hormone or analogs thereof.Type: GrantFiled: February 24, 1992Date of Patent: October 26, 1993Assignee: Bio-Technology General Corp.Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi
-
Patent number: 5198361Abstract: An improved vector upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.Type: GrantFiled: January 3, 1991Date of Patent: March 30, 1993Assignee: Bio-Technology General Corp.Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi
-
Patent number: 4997916Abstract: A method is provided for recovering a purified animal growth hormone or a polypeptide analog thereof having substantially the same amino acid sequence as, and the biological activity of, the corresponding naturally-occurring animal growth hormone from a bacterial cell in which the animal growth hormone or polypeptide analog has been produced by means of expression of a plasmid encoding the hormone or polypeptide analog which comprises: (a) disrupting the cell wall of the bacterial cell in a buffered neutral pH solution so as to produce a lysate containing precipitated hormone or polypeptide analog; (b) recovering the resulting precipitated hormone or polypeptide analog; (c) suspending the precipitated hormone or polypeptide analog so recovered in distilled water; (d) treating the resulting precipitate-containing suspension with a sodium hydroxide solution having an alkaline pH of about 11.Type: GrantFiled: March 7, 1989Date of Patent: March 5, 1991Assignee: Bio-Technology General Corp.Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi
-
Patent number: 4871835Abstract: Analogs of hGH having the activity of naturally occurring hGH and a similar amino acid sequence varying from the sequence of natural hGh by the addition of one or more amino acids, e.g. methione or methionine-leucine, to the N-terminus of natural hGH have been produced, recovered and purified. Such analogs may be incorporated into pharmaceutical compositions and administered to a subject to increase the level of hGH in the subject.Analogs of hGH which comprise the amino acid sequence of natural hGH from the N-terminus of which one or more amino acids have been deleted, e.g. Met.sup.14 hGh, have been produced, recovered and purified. Such analogs may be incorporated into pharmaceutical compositions and administered to a subject to lower the level of hGH in the subject.A plasmid has been constructed which directs the expression of an analog of hGH having the amino acid sequence methionine-leucine added to the N-terminus of natural hGH.Type: GrantFiled: January 14, 1985Date of Patent: October 3, 1989Assignee: Bio-Technology General Corp.Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Pinhas E. Zeelon, Menachem Zeevi
-
Patent number: 4831120Abstract: An improved vector upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.Type: GrantFiled: July 3, 1985Date of Patent: May 16, 1989Assignee: Bio-Technology General Corp.Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi